TPS 5603

Trial in Progress Update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a New Cohort With First-Line Tisotumab Vedotin + Pembrolizumab + Carboplatin ± Bevacizumab in Recurrent/ Metastatic Cervical Cancer

Ignace Vergote,[1,2] Mansoor Mirza,[3] Jalid Sehouli,[4] Domenica Lorusso,[5] Fatih Kose,[6] David Cibula,[7] Anneke Westermann,[8,9] Dearbhaile Collins,[10,11] Susana Banerjee,[12,13] Ana Oaknin,[14] Ibrahima Soumaoro,[15] Shweta Jain,[16] Bradley J. Monk[17,18]

[1]Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium; [2]Leuven Cancer Institute University Hospital, Leuven, Belgium; [3]Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; [4]Charity University Medicine Berlin, Berlin, Germany; [5]Fondazione Policlinico Universitario Agnostino Gemelli IRCCS, Rome, Italy; [6]Başkent University, Adana, Turkey; [7]General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic; [8]Dutch Gynaecological Oncology Group (DGOG), Amsterdam, Netherlands; 9Amsterdam University Medical Centers, Amsterdam, Netherlands; [10]Cork University Hospital, Cork, Ireland; [11]Cancer Trials Ireland, Dublin, Ireland; [12]The Royal Marsden NHS Foundation Trust, London, United Kingdom; [13]National Cancer Research Institute, London, United Kingdom; [14]d'Hebron Institute of Oncology (VHIO), Hospital Universitario Valle de Hebrón, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; [15]Genmab US, Inc., Princeton, NJ, USA; [16]Seagen Inc., Bothell, WA, USA; [17]GOG Foundation, Creighton University, Phoenix, Arizona, USA; [17]University of Arizona, Phoenix, Arizona, USA

BACKGROUND

- Recurrent/metastatic cervical cancer (r/mCC) has a poor prognosis, with a 5-year survival rate of 18% in patients with distant metastases[1]
- Until recently, first-line (1L) treatment for r/mCC was limited to taxane-platinum combinations with bevacizumab (bev), as recommended by regional guidelines[2-4]
- Following KN-826, the immune checkpoint inhibitor pembrolizumab (pembro) was approved in the United States (US) and Europe in combination with chemotherapy, with or without bev, for patients with r/mCC whose tumors express programmed death–ligand 1 (PD-L1; with a combined positive score of ≥1)[5-8]
  - Pembro + chemotherapy ± bev demonstrated survival benefit over placebo (overall survival [OS] hazard ratio [HR]: 0.64; progression-free survival [PFS] HR: 0.62)
  - The 24-month OS of 53% vs 42% in the pembro vs placebo group suggests a need for more effective options with long-term improvement
- Additional treatment approaches are needed so clinical benefit is achieved in more patients, regardless of biomarker selection

Tisotumab Vedotin

- Tissue factor (TF) plays a role in the tumor growth, angiogenesis, and metastasis of cancer[9] and is highly prevalent in cervical cancer, including squamous and adenocarcinoma histologic subtypes[9-11]
- Tisotumab vedotin (TV) is an investigational TF-directed antibody-drug conjugate comprising a fully human monoclonal antibody specific for TF, the microtubule-disrupting agent monomethyl auristatin E (MMAE), and a protease-cleavable linker that covalently links MMAE to the antibody (**Figure 1**)[12,13]
  - Once internalized by TF-expressing cells, MMAE is released in the endolysosome, resulting in cell cycle arrest and apoptotic cell death in actively dividing cells
  - TV has antitumor activity in multiple tumor types and kills tumor cells by direct cytotoxicity, bystander cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and in a manner consistent with immunogenic cell death
- Based on clinically meaningful and durable tumor response from the innovaTV 204 study (NCT03438396; objective response rate: 24%; median duration of response: 8.3 months), TV monotherapy received accelerated approval from the US Food and Drug Administration for use in patients with previously treated r/mCC[14,15]

Study Rationale

- To further improve outcomes in r/mCC, we combined TV with other agents with nonoverlapping modes of action and known activity in cervical cancer
- The ENGOT-cx8/GOG-3024/innovaTV 205 (NCT03786081) study explored the combination of TV + pembro, TV + carboplatin (carbo), and TV + bev; early results suggest potentially enhanced antitumor activity with a tolerable safety profile[14]
  - Following dose escalation, the safety and recommended phase 2 dose (RP2D) of TV were confirmed in patients with r/mCC who progressed on or after SOC, or were ineligible or intolerant to SOC for r/mCC, with **TV + bev** (Arm A)**, TV + pembro** (Arm B), and **TV + carbo** (Arm C) (2.0 mg/kg once every three weeks)[16]
  - Interim safety and efficacy data from 2 dose-expansion cohorts, **1L TV + carbo** (Arm D) and **2L/3L TV + pembro** (Arm F), were reported thereafter[17]
  - Safety and efficacy data of a third dose-expansion cohort for **1L TV + pembro** (Arm E) was recently reported, as was updated safety and efficacy data from Arm D and Arm F (Lorusso et al. ASCO; June 3-7, 2022; Chicago, IL; Abstract number: 5507)
- This report describes the design of Arm H (**Figure 2**), a new, ongoing dose-expansion cohort in the innovaTV 205 study to evaluate the combination of **1L TV, pembro, and carbo, ± bev** (if permitted per local practice and if the patient is eligible per investigator assessment) in a mixed population of patients with PD-L1+ and PD-L1- tumors (see **Figure 3** for participating countries)

Figure 1. Proposed Mechanism of Action of TV



APC, antigen presenting cell; ER, endoplasmic reticulum; mc-vc, maleimidocaproyl-valine-citrulline; MMAE, monomethyl auristatin E; PD-1, programmed cell death protein 1; PD-L1/L2, programmed cell death ligands 1/2.

ELIGIBILITY

Key Inclusion Criteria

- Have squamous, adenosquamous, or adenocarcinoma of the cervix
- Must not have received prior systemic therapy for recurrent or stage IVb cervical cancer
- Be aged at least 18 years on the day of signing informed consent
- Have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1

Key Exclusion Criteria

- Active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis
- Has clinically relevant bilateral hydronephrosis that cannot be alleviated by ureteral stents or percutaneous drainage
- Has clinical signs or symptoms of gastrointestinal obstruction and requires parenteral hydration and or nutrition; postoperative obstructions within 4 weeks of abdominal surgery are permitted
- Has clinically significant bleeding issues or risks
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator or sponsor
- Has known allergies, hypersensitivity, or intolerance to any part of the specific trial treatment regimen selected for the patient or other platinum-containing compounds as applicable to the assigned treatment regimen

STUDY DESIGN

Figure 2. Study Design of ENGOT-cx8/GOG-3024/innovaTV 205 Arm H



Arm H (outlined in yellow box) is described is this presentation. After the first 6 patients treated with the quadruplet combination in Arm H have undergone the 21-day dose-limiting toxicity (DLT) evaluation by the safety committee and there are fewer than 2 DLTs, enrollment will be expanded to approximately 30 patients (including those eligible [quadruplet combination] and ineligible [triplet combination] to receive bev). If ≥ 2 patients experience a DLT during the DLT period, enrollment will be paused, and the safety committee will perform a comprehensive review to determine if treatment will be continued any further with or without a modified dose or schedule or be discontinued. Data will be reviewed on an ongoing basis throughout the trial.

1/2/3L, first-, second-, third-line; AUC, area under the curve; bev, bevacizumab; carbo, carboplatin; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenously; MTD, maximum-tolerated dose; ORR, overall response rate; pembro, pembrolizumab; Q3W, once every three weeks; RP2D, recommended phase 2 dose; TV, tisotumab vedotin.

Figure 3. Countries Participating in ENGOT-cx8/GOG-3024/innovaTV 205 (green)



OBJECTIVES

Primary Objective	Endpoint
Evaluate the antitumor activity of 1L TV in combination in patients with r/mCC	Confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Secondary Objectives	**Endpoints**
Assess safety and tolerability of TV in combination	Adverse events and safety laboratory parameters
Evaluate durability of response of TV in combination	Duration of response per RECIST v1.1 Time to response per RECIST v1.1
Evaluate clinical efficacy with TV in combination	PFS per RECIST v1.1 OS
Evaluate the pharmacokinetics and immunogenicity of TV in combination	Pharmacokinetics concentrations and anti-drug antibodies associated with TV
Exploratory Objectives	**Endpoints**
Explore the relationship between biomarkers and clinical response	TF and PD-L1 expression in tumor biopsies, circulating TF, proteomic analyses, and genomic signatures
Assess potential pharmacodynamic biomarkers	Circulating TF and proteomic analyses

SUMMARY

- This study is enrolling adult patients with recurrent or stage IVb squamous, adenosquamous, or adenocarcinoma of the cervix with an ECOG PS of 0 or 1
- Patients will be treated every 3 weeks with the **RP2D of TV (2.0 mg/kg)**
  - **+ Carbo (area under the curve 5 mg/mL), pembro (200 mg), and bev (15 mg/kg), or**
  - **+ Carbo (area under the curve 5 mg/mL) and pembro (200 mg)**
- The expansion of enrollment of the quadruplet regimen to 30 patients is contingent upon the occurrence of fewer than 2 DLTs among the first 6 patients enrolled over a treatment evaluation period of 21 days
  - If there are fewer than 2 DLTs, enrollment will be expanded to approximately 30 patients
- The primary end point of this dose-expansion phase is confirmed objective response rate per RECIST v1.1
- Secondary end points include duration of response, time to response, PFS, OS, and safety
- Enrollment is ongoing in the US and Europe

ACKNOWLEDGMENTS

The authors thank all the investigators and site staff as well as the participants and their families and caregivers. Medical writing assistance was provided by ApotheCom (Yardley, PA, USA) and was funded Genmab A/S (Copenhagen, Denmark) and Seagen Inc. (Bothell, USA). This study is in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

REFERENCES

1. The American Cancer Society. https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/survival.html. Accessed May 11, 2022.
2. Kitagawa R et al. *J Clin Oncol.* 2015;33:2129-2135.
3. Tewari KS et al. *N Engl J Med.* 2014;370:734-743.
4. Ebina Y et al. *Int J Clin Oncol.* 2019;24:1-19.
5. Keytruda [package insert]. Merck Sharp & Dohme Corp.; April 2020.
6. Merck & Co., Inc. KEYTRUDA® (pembrolizumab) (press release). https://www.nasdaq.com/press-release/european-commission-approves-mercks-keytrudar-pembrolizumab-plus-chemotherapy-with-or. Accessed May 11, 2022.
7. National Comprehensive Cancer Network. https://www.nccn.org/patients/guidelines/content/PDF/cervical-patient-guideline.pdf. Accessed May 11, 2022.
8. Colombo N et al. *N Engl J Med.* 2021;385:1856-1867.
9. Versteeg HH et al. *Mol Med.* 2004;10:6-11.
10. Zhao X et al. *Exp Ther Med.* 2018;16:4075-4081.
11. Cocco E et al. *BMC Cancer.* 2011;11:263.
12. Breij EC et al. *Cancer Res.* 2013;74:1214-1226.
13. de Goeij BE et al. *Mol Cancer Ther.* 2015;14:1130-1140.
14. Coleman RL et al. *Lancet Oncol.* 2021;22:609-619.
15. Tivdak (tisotumab vedotin-tftv) for injection, for intravenous use [package insert]. Genmab US Inc., 2021.
16. Monk BJ et al. IGCS; Aug 30- Sep 2, 2021; Rome, Italy; O013/#573
17. Vergote I et al. ESMO; Sep 16-21, 2021; Paris, France; #723MO

Presented at the American Society of Clinical Oncology (ASCO) Congress; Chicago, Illinois; June 3-7, 2022

This study was supported by Genmab A/S and Seagen Inc. in collaboration with Merck & Co., Inc.